Biopharmaceutical News and Research

RSS

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Opinions: Investing in science, technology; Indian public-private partnership for NTDs; U.S. global food security investments; Clinton's statements on PEPFAR; U.S. foreign aid; primary care

"Now is the time to support science and technology - especially in difficult economic times. It is the right thing to do, and it makes good economic sense," Alex Dehgan, science and technology adviser to the USAID administrator, and Kaitlin Christenson, coalition director for the Global Health Technologies Coalition, write in an opinion piece appearing on The Hill's "Congress Blog."

10 Mar 2011

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics, announced today it has received an Israeli Patent for its Ultrapure Transferrin to be used in Pharmaceutical Compositions.

10 Mar 2011

PPD introduces new online portal to enhance patient connectivity, improve retention in clinical trials

PPD, Inc. today announced it has launched an innovative online portal linking clinical trial participants with biopharmaceutical companies, physicians and health care resources to enhance patient connectivity and improve retention in clinical trials.

10 Mar 2011

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.

9 Mar 2011

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

In a move to improve efficiency by reducing paper in their respective operations, Forest Laboratories and the Allergy Asthma Research Institute have joined SAFE-BioPharma Association. They now have access to the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

9 Mar 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office in relation to the Company's RECALL-VAXTM technology platform.

9 Mar 2011

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

Grifols receives FDA approval for Alphanate to treat vCJD

Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration for revised labeling for Alphanate Antihemophilic Factor/von Willebrand Factor Complex indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob Disease.

5 Mar 2011

New HQ of David H. Koch Institute for Integrative Cancer Research officially dedicated

The new seven-story headquarters of the David H. Koch Institute for Integrative Cancer Research at MIT, where scientists and engineers are working together to pursue new ways to treat, detect and prevent cancer, will be officially dedicated today at 4 p.m.

5 Mar 2011

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the European Commission has approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. FIRAZYR is the first and only treatment for acute Type I and Type II hereditary angioedema (HAE) attacks licensed for self-administration in Europe.

4 Mar 2011

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011.

3 Mar 2011

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.

3 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

HP announces innovative drug research application for its inkjet technology

HP today announced an innovative drug research application for its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.

1 Mar 2011

Nile plans to develop novel therapeutics for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.

1 Mar 2011

Biopharmaceutical News and Research

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Opinions: Investing in science, technology; Indian public-private partnership for NTDs; U.S. global food security investments; Clinton's statements on PEPFAR; U.S. foreign aid; primary care

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

PPD introduces new online portal to enhance patient connectivity, improve retention in clinical trials

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

USPTO grants new patent to Intellect's Alzheimer's vaccine

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Grifols receives FDA approval for Alphanate to treat vCJD

New HQ of David H. Koch Institute for Integrative Cancer Research officially dedicated

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Rockwell Medical fourth quarter net loss increases to $1.7 million

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

HP announces innovative drug research application for its inkjet technology

Nile plans to develop novel therapeutics for ADHF

How to optimize your cell line development eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News